ENDRA Life Sciences Inc. (NDRA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 600K 1.2M 1.8M Q4 '16: 34.1K Q1 '17: 30.8K Q2 '17: 32K Q3 '17: 63.3K Q4 '17: 122.6K Q1 '18: 228.7K Q2 '18: 263.1K Q3 '18: 287.9K Q4 '18: 262.6K Q1 '19: 212.3K Q2 '19: 259.3K Q3 '19: 287.3K Q4 '19: 412.4K Q1 '20: 470.6K Q2 '20: 517K Q3 '20: 556.5K Q4 '20: 581.9K Q1 '21: 627.9K Q2 '21: 749.9K Q3 '21: 885.7K Q4 '21: 1.1M Q1 '22: 1.3M Q2 '22: 1.3M Q3 '22: 1.5M Q4 '22: 1.4M Q1 '23: 1.3M Q2 '23: 1.2M Q3 '23: 999.5K Q4 '23: 820.6K Q1 '24: 877.6K Q2 '24: 792.8K Q3 '24: 632.6K Q4 '24: 571K Q1 '25: 401.4K Q2 '25: 307.3K Q3 '25: 269.4K Q4 '25: 189.5K Q1 '26: 124.8K Q2 '26: 61.7K Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 200K 400K 600K Q2 '17: 286K Q3 '17: 454.8K Q4 '17: 178.8K Q1 '18: 185K Q2 '18: 178.7K Q3 '18: 9.9K Q4 '18: 6.2K Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q2 '17 Q4 '17 Q2 '18 Q4 '18 Q2 '19 Q4 '19

Operating Income TTM

-15M -10M -5M 0 5M 10M 15M Q4 '16: -1.8M Q1 '17: -1.8M Q2 '17: -2.3M Q3 '17: -2.6M Q4 '17: -4.6M Q1 '18: -7.1M Q2 '18: -7.9M Q3 '18: -9.3M Q4 '18: -9M Q1 '19: -8.9M Q2 '19: -9.4M Q3 '19: -9.7M Q4 '19: -10.8M Q1 '20: -11.2M Q2 '20: -11.8M Q3 '20: -12.4M Q4 '20: -11.5M Q1 '21: -11M Q2 '21: -11.3M Q3 '21: -10.7M Q4 '21: -11.5M Q1 '22: -11.8M Q2 '22: -12.1M Q3 '22: -12.9M Q4 '22: -13.2M Q1 '23: -13.2M Q2 '23: -12.7M Q3 '23: -12.4M Q4 '23: -10.5M Q1 '24: -10.4M Q2 '24: -9.6M Q3 '24: -8M Q4 '24: -10.8M Q1 '25: -9.5M Q2 '25: -8.6M Q3 '25: -8.4M Q4 '25: -5.8M Q1 '26: -6.5M Q2 '26: -6.6M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-15M -10M -5M 0 5M 10M 15M Q4 '16: -2.8M Q1 '17: -3.1M Q2 '17: -3.8M Q3 '17: -3.8M Q4 '17: -5.4M Q1 '18: -7.5M Q2 '18: -7.9M Q3 '18: -9.7M Q4 '18: -9.8M Q1 '19: -9.7M Q2 '19: -10.2M Q3 '19: -10.9M Q4 '19: -13.3M Q1 '20: -13.9M Q2 '20: -14.4M Q3 '20: -14.3M Q4 '20: -11.7M Q1 '21: -10.7M Q2 '21: -11M Q3 '21: -10.4M Q4 '21: -11.2M Q1 '22: -11.8M Q2 '22: -12.2M Q3 '22: -13M Q4 '22: -13.2M Q1 '23: -13.3M Q2 '23: -12.2M Q3 '23: -11.9M Q4 '23: -10.1M Q1 '24: -9.9M Q2 '24: -9.6M Q3 '24: -8.8M Q4 '24: -11.5M Q1 '25: -9.8M Q2 '25: -8.8M Q3 '25: -8M Q4 '25: -7M Q1 '26: -7.3M Q2 '26: -5.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '16: -1.3M Q1 '17: -1.5M Q2 '17: -1.9M Q3 '17: -2.5M Q4 '17: -3.3M Q1 '18: -5.5M Q2 '18: -6.3M Q3 '18: -7.2M Q4 '18: -7.7M Q1 '19: -7.8M Q2 '19: -7.6M Q3 '19: -8.6M Q4 '19: -8.6M Q1 '20: -9.1M Q2 '20: -10.9M Q3 '20: -10.6M Q4 '20: -10.7M Q1 '21: -10.6M Q2 '21: -9.9M Q3 '21: -10.5M Q4 '21: -11.1M Q1 '22: -11.3M Q2 '22: -11.8M Q3 '22: -12.3M Q4 '22: -12.8M Q1 '23: -12.2M Q2 '23: -11.1M Q3 '23: -10.5M Q4 '23: -9.5M Q1 '24: -9.2M Q2 '24: -9M Q3 '24: -8.1M Q4 '24: -7.4M Q1 '25: -6.5M Q2 '25: -5.6M Q3 '25: -5.1M Q4 '25: -5.2M Q1 '26: -5M Q2 '26: -4.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q2 '18: -6.3M Q3 '18: -7.3M Q4 '18: -7.8M Q1 '19: -7.9M Q2 '19: -7.7M Q3 '19: -8.6M Q4 '19: -8.6M Q1 '20: -9.2M Q2 '20: -11M Q3 '20: -10.6M Q4 '20: -10.8M Q1 '21: -10.7M Q2 '21: -10M Q3 '21: -10.7M Q4 '21: -11.2M Q1 '22: -11.4M Q2 '22: -12M Q3 '22: -12.5M Q4 '22: -13M Q1 '23: -12.3M Q2 '23: -11.2M Q3 '23: -10.5M Q4 '23: -9.6M Q1 '24: -9.2M Q2 '24: -9M Q3 '24: -8.1M Q4 '24: -7.4M Q1 '25: -6.6M Q2 '25: -5.6M Q3 '25: -5.1M Q4 '25: -5.2M Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 900K 1.8M 2.7M Q3 '24: 246.8K Q1 '25: 557.6K Q2 '25: 717.1K Q3 '25: 761.2K Q1 '26: 1.2M Q2 '26: 2.5M Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '16: -3.84 Q1 '17: -4.35 Q2 '17: -3.93 Q3 '17: -2.81 Q4 '17: -2.50 Q1 '18: -2.19 Q2 '18: -2.07 Q3 '18: -2.54 Q4 '18: -2.17 Q1 '19: -1.82 Q2 '19: -1.66 Q3 '19: -1.42 Q4 '19: -2.34 Q1 '20: -2.26 Q2 '20: -2.15 Q3 '20: -1.84 Q4 '20: -0.86 Q1 '21: -0.63 Q2 '21: -0.51 Q3 '21: -0.42 Q4 '25: -8.92 Q1 '26: -8.15 Q2 '26: -6.38 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.